AU2020284038A1 - ActRII-binding proteins and uses thereof - Google Patents

ActRII-binding proteins and uses thereof Download PDF

Info

Publication number
AU2020284038A1
AU2020284038A1 AU2020284038A AU2020284038A AU2020284038A1 AU 2020284038 A1 AU2020284038 A1 AU 2020284038A1 AU 2020284038 A AU2020284038 A AU 2020284038A AU 2020284038 A AU2020284038 A AU 2020284038A AU 2020284038 A1 AU2020284038 A1 AU 2020284038A1
Authority
AU
Australia
Prior art keywords
seq
amino acid
acid sequence
actrii
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020284038A
Other languages
English (en)
Inventor
Jonathan Belk
Roselyne CASTONGUAY
Asya Grinberg
Ravindra Kumar
Dianne Sako
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acceleron Pharma Inc
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of AU2020284038A1 publication Critical patent/AU2020284038A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020284038A 2019-05-30 2020-05-29 ActRII-binding proteins and uses thereof Pending AU2020284038A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962854625P 2019-05-30 2019-05-30
US62/854,625 2019-05-30
PCT/US2020/035148 WO2020243448A1 (en) 2019-05-30 2020-05-29 Actrii-binding proteins and uses thereof

Publications (1)

Publication Number Publication Date
AU2020284038A1 true AU2020284038A1 (en) 2021-12-02

Family

ID=73553540

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020284038A Pending AU2020284038A1 (en) 2019-05-30 2020-05-29 ActRII-binding proteins and uses thereof

Country Status (8)

Country Link
US (1) US12545736B2 (https=)
EP (1) EP3976630A4 (https=)
JP (2) JP7669291B2 (https=)
KR (1) KR20220029563A (https=)
CN (1) CN114127087A (https=)
AU (1) AU2020284038A1 (https=)
CA (1) CA3142149A1 (https=)
WO (1) WO2020243448A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020284038A1 (en) 2019-05-30 2021-12-02 Acceleron Pharma Inc. ActRII-binding proteins and uses thereof
JP2024511315A (ja) * 2021-03-10 2024-03-13 アクセルロン ファーマ インコーポレイテッド Ａｃｔｒｉｉ－ａｌｋ４アンタゴニスト及び心不全の治療方法
US20250064952A1 (en) * 2021-03-10 2025-02-27 Acceleron Pharma Inc. Actrii-alk4 antagonists and methods of treating heart failure
JP2024532345A (ja) * 2021-09-03 2024-09-05 ラエクナ セラピューティクス シャンハイ カンパニー リミテッド 抗ａｃｖｒ２ａ抗体及びその使用
AU2024317572A1 (en) 2023-07-31 2026-03-12 Sixpeaks Bio Ag Antibody conjugates and fusion proteins
WO2025026353A1 (en) * 2023-08-01 2025-02-06 Laekna Therapeutics Shanghai Co., Ltd. Anti-acvr2b antibodies and uses thereof
WO2025068454A1 (en) * 2023-09-28 2025-04-03 Sixpeaks Bio Ag Antibodies targeting actriia and actriib
CN121344183B (zh) * 2025-12-18 2026-03-27 成都医学院 检测ACVR2b的试剂在制备慢性肾脏病血管钙化诊断试剂盒中的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
JP5766179B2 (ja) 2009-04-27 2015-08-19 ノバルティス アーゲー 筋肉増殖を増加させるための組成物および方法
US8765385B2 (en) 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
GR1007832B (el) 2011-11-21 2013-02-14 Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
JP2015525230A (ja) 2012-06-11 2015-09-03 アムジエン・インコーポレーテツド デュアル受容体アンタゴニスト性抗原結合タンパク質およびその使用
WO2014172448A2 (en) * 2013-04-17 2014-10-23 Anaptysbio, Inc. Antibodies directed against activin receptor type ii (actrii)
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
PT3286206T (pt) 2015-04-22 2021-04-01 Biogen Ma Inc Novas proteínas híbridas bloqueadoras de ligando actriib para tratar doenças de desgaste muscular
AU2017222526A1 (en) 2016-02-22 2018-08-23 Acceleron Pharma Inc. ActRII antagonists for use in increasing immune activity
JP6987072B2 (ja) * 2016-03-10 2021-12-22 アクセレロン ファーマ インコーポレーテッド アクチビン２型受容体結合タンパク質及びその使用
FI3600415T3 (fi) 2017-03-24 2025-12-05 Novartis Ag Aktiviinireseptorin tyypin ii reseptorin vastainen vasta-aine käytettäväksi sydämen vajaatoiminnan hoidossa
AU2020284038A1 (en) 2019-05-30 2021-12-02 Acceleron Pharma Inc. ActRII-binding proteins and uses thereof

Also Published As

Publication number Publication date
EP3976630A4 (en) 2024-03-20
WO2020243448A1 (en) 2020-12-03
KR20220029563A (ko) 2022-03-08
JP2025118664A (ja) 2025-08-13
WO2020243448A8 (en) 2022-05-05
JP2022534966A (ja) 2022-08-04
US12545736B2 (en) 2026-02-10
JP7669291B2 (ja) 2025-04-28
CN114127087A (zh) 2022-03-01
EP3976630A1 (en) 2022-04-06
US20220242956A1 (en) 2022-08-04
CA3142149A1 (en) 2020-12-03

Similar Documents

Publication Publication Date Title
US20240374671A1 (en) Activin Type 2 Receptor Binding Proteins and Methods of Making Them
US12545736B2 (en) ActRII-binding proteins and uses thereof
US11708414B2 (en) ALK7 binding proteins and uses thereof
US12365736B2 (en) ALK7 binding proteins and uses thereof
HK40095415A (zh) 活化素2型受体结合蛋白及其用途
HK40003457A (en) Activin type 2 receptor binding proteins and uses thereof
HK40003457B (en) Activin type 2 receptor binding proteins and uses thereof
HK40003020A (en) Alk7 binding proteins and uses thereof